Topical PP405 May Revive Decade Dormant Hair Follicles by Flipping a Metabolic Switch
The clinical candidate causing some excitement for application in androgenetic alopecia is PP405, an investigational medicine developed by Pelage Pharmaceuticals. Presentations at the AAD 2026 meeting in Denver and the SID meeting in Chicago highlight PP405 as the first therapy to successfully target dormant hair follicle stem cells directly at the level of their metabolism.
